Wall Street May Have 'Written Off' Genomic Health's Colon Cancer Dx, But Survey Shows Some Docs Haven't

Even though Genomic Health's Oncotype DX recurrence test for colorectal cancer failed to meet its chemotherapy benefit endpoint, investment group Thomas Wiesel is optimistic after a survey of 47 physicians and researcher that the strength of the Oncotype DX brand and the lack of molecular profiling options in the colorectal cancer setting will drive adoption of the test.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.